Or Refractory B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS research · 2026-03-19
  Clinical Trial Update: A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) [Phase 1]

  Phase 1 study evaluating MK-1045 (CN201) for safety and early activity in relapsed or refractory B-cell non-Hodgkin lymphoma; recruitment is…

• CLINICAL_TRIALS research · 2026-01-16
  Clinical Trial Update: Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [NA]

  A clinical study is evaluating the safety and efficacy of a CD20/CD19 cell injection for relapsed or refractory B-cell non-Hodgkin lymphoma,…

• CLINICAL_TRIALS research · 2022-12-16
  Clinical Trial Update: Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation [Phase 2]

  Phase 2 trial of tazemetostat in relapsed or refractory B-cell non-Hodgkin's lymphoma with EZH2 mutation completed.